⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12173604 | 1.00 | — | — | |
| SCHEMBL2387161 | 1.00 | — | — | |
| SCHEMBL25590952 | 1.00 | — | — | |
| SCHEMBL3527710 | 0.82 | — | — | |
| SCHEMBL22236818 | 0.82 | — | — | |
| SCHEMBL7496834 | 0.82 | — | — | |
| SCHEMBL3527714 | 0.82 | — | — | |
| SCHEMBL17207640 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL30832300 | 0.80 | CHRM1 (0.33) | — | |
| SCHEMBL16838128 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115551855-A | Small molecule inhibitors of galectin-3 | 百时美施贵宝公司 | 2022-12-30 | — | — | CN | disclosed |
| US-11266643-B2 | Triaryl compounds for treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| WO-2021262627-A1 | METHODS OF TREATING CANCER USING HETEROARYL-BIPHENYL AMIDE DERIVATIVES | CHEMOCENTRYX, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20210380606-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2021-12-09 | — | — | US | disclosed |
| WO-2021076691-A1 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021076688-A1 | HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20200383979-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2020-12-10 | — | — | US | disclosed |
| WO-2020232256-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. (US) | 2020-11-19 | — | — | WO | disclosed |